Lead Product(s): Imeglimin
Therapeutic Area: Endocrinology
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2020
Two drug-drug interaction studies assessed the effect of repeated co-administration of commonly prescribed medications, metformin or sitagliptin (Januvia®; Merck & Co.), with Imeglimin.